HUTCHMED (China) (HCM) R&D Update summary

Late-stage pipeline progress and product updates

• Fruquintinib approved in China, US, and Europe for late-stage colorectal cancer, with strong sales and ongoing launches in new markets.

• Savolitinib approved in China for MET exon 14 skipping NSCLC; NDA submitted for expanded indications and US filing expected based on pivotal SAVANNAH study.

• Surufatinib advancing in first-line pancreatic ductal adenocarcinoma with promising data and market leadership in neuroendocrine tumors in China.

• HMPL-306, a dual IDH1/2 inhibitor, entered phase III for AML, showing high potency, selectivity, and brain penetration.

• Tazemetostat and HMPL-689 progressing in late-stage trials for lymphoma and cholangiocarcinoma, respectively.

Sovleplenib/Savolitinib for autoimmune diseases (ITP, wAIHA)

• Sovleplenib, a selective Syk inhibitor, showed a 48.4% durable response rate vs 0% for placebo in Phase III ESLIM-01 for ITP, with rapid onset and improved quality of life.

• Consistent efficacy across subgroups, including heavily pretreated and TPO-RA refractory patients.

• Well-tolerated safety profile with low GI toxicity, no thromboembolic events, and low discontinuation rates.

• Large addressable ITP market in China ($500m–$700m) and globally, with ongoing international development and expansion into wAIHA and other autoimmune indications.

• In wAIHA, Phase II trial showed 66.7% overall response and 47.6% durable response at 24 weeks, with rapid and sustained hemoglobin improvement.

Surufatinib in pancreatic cancer

• Combination with PD-1 and chemotherapy in first-line pancreatic cancer showed 50% response rate and median PFS of 9 months.

• Phase II/III registration study underway in China for first-line metastatic PDAC.

• Maintains strong market position in neuroendocrine tumors in China, with ongoing efforts to defend and expand market share.

• Surufatinib, already launched for NETs, is being developed for first-line PDAC, a market with high unmet need and limited effective therapies.

• Combination therapy showed improved mPFS (9.0 vs 5.8 months) and MOS (13.3 vs ~7–11 months) compared to standard AG regimen.